Evidence map›Paper›PMID 22271672›Full record

ArticleThe Journal of infectious diseases2012

CCR5 deficiency mitigates the deleterious effects of tumor necrosis factor α antagonism in murine histoplasmosis.

Danielle N Kroetz, George S Deepe

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Histoplasma Capsulatum: Mechanisms for Pathogenesis.Current topics in microbiology and immunology · 2019
    Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Danielle N KroetzDepartment of Molecular Genetics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
George S Deepe
Laboratory of Molecular Genetics · PLVeterans Health Administration · US

Funding

Immunopathogenesis in HistoplasmosisR01AI073337 · NIAID · UNIVERSITY OF CINCINNATI · PI DEEPE, GEORGE S. · 2008 to 2012
$2.0M
Chemokine-Cytokine Nexus in Fungal ImmunityR01AI083313 · NIAID · UNIVERSITY OF CINCINNATI · PI DEEPE, GEORGE S. · 2010 to 2014
$1.9M
Chemokine-Cytokine Nexus in Fungal ImmunityR56AI083313 · NIAID · UNIVERSITY OF CINCINNATI · PI DEEPE, GEORGE S. · 2009 to 2009
$294k
NIAID NIH HHS AI-073337NIAID NIH HHS AI-083313NIAID NIH HHS R01 AI073337NIAID NIH HHS R01 AI083313NIAID NIH HHS R56 AI083313
6 · The paper itself

Abstract

In murine histoplasmosis, tumor necrosis factor α (TNF-α) antagonism increases the number of regulatory T cells (Tregs) in lungs, and these cells profoundly hinder protective immunity. Because CCR5 mediates Treg homing and proliferation, we determined the outcome of antagonizing TNF-α in CCR5(-/)(-) mice infected with Histoplasma capsulatum. The absence of CCR5 attenuated the severity of infection associated with TNF-α neutralization. Infected controls given anti-TNF-α had a 10-fold increase in the number of Tregs in lungs compared with a <2-fold increase in CCR5(-/)(-) lungs. This difference was partially attributable to impaired homing in the absence of CCR5. Neutralization of TNF-α-enhanced CCR5 ligands in wild-type lungs thus promotes a gradient between lungs and the thymus. This study elucidates the interplay between TNF-α and CCR5 in histoplasmosis. The data suggest that targeting CCR5 may improve host immunity in individuals receiving TNF-α antagonists during infection.

Indexed as

AnimalsAntibodies, MonoclonalCell ProliferationHistoplasmaHistoplasmosisLungMiceMice, Inbred C57BLMice, KnockoutReceptors, CCR5T-Lymphocytes, RegulatoryTumor Necrosis Factor-alphaAntibodies, MonoclonalReceptors, CCR5Tumor Necrosis Factor-alpha

Identifiers

PMID22271672
PMCPMC3282568
OpenAlexW2103888071

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.